EMERYVILLE, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- A monograph on NovaBay’s lead Aganocide® NVC-422 was recently published in the journal Drugs of the Future. NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), is a clinical-stage biotechnology company developing its pipeline of first-in-class, broad-spectrum, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections The article titled “NVC-422,” was written by Rabih Darouiche, MD of Baylor College of Medicine in collaboration with the product development team from NovaBay Pharmaceuticals.
